July 24, 2020
Nobody is in danger of being irreparably harmed by California's new law banning most so-called pay-for-delay deals, the Ninth Circuit said Friday in a ruling that zapped a generic-drug industry association's challenge to the statute.
July 16, 2020
A Ninth Circuit panel on Thursday pressed the attorney for a generic-drug industry association during oral arguments to explain how California's state law prohibiting most so-called pay-for-delay settlements poses a risk of imminent danger to pharmaceutical companies.
March 20, 2020
A pharmaceutical trade group challenging a California law barring most pay-for-delay settlements between generic and branded drugmakers told the Ninth Circuit on Thursday that its lawsuit should move forward because the measure has already impacted its members' ability to run their businesses.
March 06, 2020
AARP and several consumer advocacy groups have urged the Ninth Circuit to uphold a new California law prohibiting most pay-for-delay settlements between generic and branded drugmakers, backing the Golden State's effort to fend off a pharmaceutical-backed challenge to the measure.
February 24, 2020
The Ninth Circuit on Monday rejected a bid from a group of generic pharmaceutical companies to block a new California law prohibiting most pay-for-delay settlements between generic and branded drugmakers.
February 06, 2020
Two trade groups and a public interest law firm on Thursday urged the Ninth Circuit to block a California state law prohibiting pay-for-delay deals between branded and generic-drug makers, saying the law could lead to never-ending litigation.
January 27, 2020
A group of pharmaceutical companies challenging a new California law banning most pay-for-delay settlements between generic and branded drugmakers urged the Ninth Circuit to pause the ban's implementation, saying the measure clashes with court precedent and would subject them to lengthy patent litigation.